Carbon Dioxide Angiography

No Results

No Results

processing….

Carbon dioxide (CO₂) gas was used as a contrast agent in the venous circulation in the 1950s and 1960s to delineate the right heart for evaluation of suspected pericardial effusion. This imaging developed from animal and clinical studies, which demonstrated that CO₂ use was safe and well tolerated with peripheral venous injections.

In the 1970s, CO₂ was used as an intra-arterial contrast agent. With the advent of digital subtraction angiography (DSA) in 1980, CO₂ angiography became a useful diagnostic tool, particularly in patients who were hypersensitive to iodinated contrast material or whose renal function was compromised. Now, with the availability of high-resolution DSA and a reliable gas delivery system, CO₂ angiography has become widely used for vascular imaging and endovascular procedures.

Because the use of CO₂ is not associated with nephrotoxicity or allergic reactions, it is increasingly being used as a contrast agent for aortography, as well as for outflow assessment, renal arteriography, and visceral angiography. The gas is the preferred contrast agent for central venography of the upper extremity; for wedged hepatic venography in order to visualize the portal venous system before transjugular intrahepatic portosystemic shunt (TIPS); and for fine-needle TIPS procedures.

CO₂ is used to guide various vascular interventions, including angioplasty and stent placement, transcatheter embolization, and endovascular abdominal aortic aneurysm (AAA) repair.

CO₂ should not be used as an arterial contrast agent in sites above the diaphragm because of the risk of gas embolism of the spinal, coronary, and cerebral arteries. CO₂ may be delivered by the hand-held syringe method, by the plastic bag system, or by the CO₂mmander and AngiAssist. These delivery systems are safe if used correctly. Because air is poorly soluble, air contamination must be prevented during the delivery of CO₂. Thorough understanding of the physical properties of CO₂ and facile catheterization technique are essential in obtaining optimal CO₂ imaging for both diagnosis and intervention. ^{[1, 2, 3, 4, 5, 6, 7, 8, 9]}

When CO₂ is injected into the blood, it is combined with water to produce carbonic acid. It becomes bicarbonate (HCO₃^–) in the blood stream; bicarbonate reverts to CO₂ before being expelled out of capillaries into the lung. Carbonic anhydrase catalyzes the conversion of CO₂ to bicarbonate and protons. CO₂ is eliminated by the lungs in a single pass. However, CO₂ bubbles that were injected into the venous system may enter the systemic circulation via the patent foramen ovale or intracardiac septal defects.

CO₂ is a colorless and odorless gas, and it cannot be visually distinguished from air. The incorrect application of technique may result in air contamination, which may cause serious complications. A thorough understanding of the unique physical properties of CO₂ is necessary for the safe and effective performance of CO₂ angiography.

CO₂ is approximately 20 times more soluble than oxygen. When injected into a vessel, CO₂ bubbles completely dissolve within 2-3 minutes; however, if the gas is trapped in a large abdominal aneurysm, it may persist, allowing gas exchange between the CO₂ and nitrogen in the blood. This exchange may result in colonic ischemia, as a result of occlusion of the inferior mesenteric artery. Two to three minutes should elapse between injections of CO₂ to prevent the localized accumulation of gas bubbles, which may produce a significant gas embolism, particularly in the pulmonary artery.

CO₂ is compressible during injection; it expands in the vessel as it exits the catheter. Clearing the fluid of the catheter by using 3-5 cc of CO₂ before injection reduces the explosive delivery. The explosive delivery is unlikely to cause vascular damage, but it may contribute to discomfort during the injection. The low viscosity and compressibility of the gas accounts for the greater sensitivity of CO₂ as a contrast agent in detecting the source of bleeding (gastrointestinal tract and traumatic bleeding), as compared with iodinated contrast material.

CO₂ is lighter than blood plasma; therefore, it floats above the blood. When injected into a large vessel such as the aorta or inferior vena cava, CO₂ bubbles flow along the anterior part of the vessel, with incomplete blood displacement along the posterior portion. Because of their anterior point of origin, the celiac and superior mesenteric arteries fill well with small volumes (2</sub>. If gas fails to fill the renal artery, the patient must be rotated so that the side of the renal artery is elevated above the level of the injection site. If the renal artery remains unfilled, catheterization of the artery and selective injection is indicated.

The buoyancy of the gas is not a problem when the vessel to be imaged is smaller than 10 mm in diameter, because the gas bubbles tend to displace the blood in more than 80% of the lumen. Elevation of the lower extremity to 15-20° in conjunction with the intra-arterial injection of 100-200 µg of nitroglycerin enhances gas flow and filling of the distal arteries in the lower extremity.

CO₂ is approximately 400 times less viscous than iodinated contrast medium. The low viscosity permits manual gas injection with small-bore catheters between the catheter and guide wire. Doses of CO₂ required for aortic imaging may be manually injected by using a 4-Fr or 5-Fr end-hole diagnostic catheter. The low viscosity accounts for better filling of collateral vessels for both arterial and venous occlusive diseases and for portal vein visualization through the hepatic sinusoids after wedged hepatic injection with CO₂.

Iodinated contrast medium mixes with blood when injected into a vessel and becomes diluted, making it less dense as it travels through collateral vessels. By contrast, CO₂ does not mix with blood, and so it does not become diluted by collateral flow.

CO₂ is less dense than iodinated contrast medium, thus requiring digital subtraction for gas imaging. The overall quality of CO₂ vascular images is slightly less than that obtained with contrast medium. Usually, multiple hand injections are required, and the radiation exposure to the operator and patient may be increased. However, CO₂ has several notable advantages, as compared with iodinated contrast medium.

CO₂ causes no allergic reaction. Because CO₂ is a natural byproduct, it cannot cause a hypersensitivity reaction. Therefore, CO₂ is an ideal alternative to iodinated contrast medium for patients who have a history of allergic reactions. No steroid preparation is needed when CO₂ is used.

CO₂ causes no renal toxicity. Experimental and clinical findings indicate that the selective injection of CO₂ into the aorta or into the renal artery is safe and causes no renal injury, even in patients with diabetes or compromised renal function. Therefore, the gas is the preferred contrast agent for renal artery angioplasty and stent placement.

CO₂ causes no hepatic toxicity. The authors have personally used CO₂ as a contrast agent for celiac, splenic, superior mesenteric, and hepatic arteriograms for patients with a variety of disorders. No injuries to the hepatic parenchyma have occurred after the injection of CO₂.

Unlimited amounts of CO₂ may be used for vascular imaging because the gas is effectively eliminated by means of respiration. However, the operator should allow sufficient time for its clearance. A minimum of 2 minutes is needed for the first CO₂ dose to completely dissolve before another dose is injected. CO₂ is particularly useful for patients with compromised cardiac and renal function who are undergoing complex vascular interventions.

No specific patient preparation is required for CO₂ angiography. The standard preparation for catheter angiography is used. Patients with a history of allergy to contrast material do not require steroid preparation. CO₂ may be used as a contrast agent for outpatient angiography.

There are no absolute contraindications to the use of CO₂. CO₂ should not be used in the thoracic aorta and in arteries above the diaphragm because of the risk of spinal, coronary, and carotid artery gas embolism. CO₂ should be used with caution in patients with pulmonary insufficiency or pulmonary hypertension because a diagnostic dose of CO₂ may cause an increase in pulmonary arterial pressure. CO₂ should not be used in patients with an intracardiac septal defect or a pulmonary arteriovenous malformation because of the possibility of paradoxical gas embolism.

Heavy sedation should be avoided during CO₂ angiography. Respiratory depression and hypotension caused by air contamination may be mistaken for adverse effects of the sedatives and/or analgesics.

All patients undergoing CO₂ angiography should be monitored with ECG and pulse oximetry; blood pressure, respiratory rate, and heart rate should also be monitored. Capnograms should be obtained if the patient is intubated. The blood pressure should be checked before the initial injection of CO₂, as well as 1, 2, and 3 minutes after the initial injection.

A significant change in any monitoring parameter suggests either that the doses of CO₂ were excessive or that air contamination has occurred. Capnography (ETCO₂) is very useful during CO₂ angiography because it allows the monitoring of both ventilatory and hemodynamic functions in real time. Micro-cap (Oridion Medical, Ltd., Jerusalem, Israel) is a handheld capnometer that is currently available. It uses microstream infrared spectroscopy to measure the respiratory rate and ETCO₂ during exhalation. A similar capnometer, Capnocheck, is available from Smiths Medical (Dublin, OH).

The CO₂ delivery system should be filled with 99.99% laboratory-grade CO₂ from a disposable cylinder (CMD, Gainesville, FL). The cylinder is supplied with highly pure gas, a valve, a regulator, a gas gauge, and a metal diaphragm with the regulator set at 18 psi. Because of the risk of injection of large volumes of CO₂, the catheter should not be directly connected to the CO₂ cylinder, which contains a large volume of CO₂ at very high pressure. CO₂ may be delivered into a vessel by use of a handheld syringe, by the plastic bag system, or by CO₂mmander with the AngiAssist (see the images below).

When a syringe is used, it should be filled directly from a CO₂ cylinder. CO₂ should not be aspirated into the syringe because this may cause air contamination. When the syringe has been filled with CO₂, its pressure should be reduced to the atmospheric level by quickly opening and closing the stopcock. The CO₂ -filled syringe should not be left on the table with the stopcock open before injection, because the CO₂ in the syringe (which has a CO₂ concentration of >99%) is rapidly replaced with air (which has a CO₂ concentration of 0.03%). The syringe method is inconvenient when multiple injections are necessary.

The plastic bag delivery system (AngioDynamics, Queensbury, NY) has been the most useful system for CO₂ delivery. However, it has been discontinued because of a serious complication in which the bag was inadvertently filled with oxygen rather than CO₂. A similar plastic bag delivery system is available from Merit Medical System, Inc. (South Jordan, Utah). The collection bag is filled with CO₂ and is connected to the reservoir port of the fluid management system. This system has airtight connections with the check valves, the injection port, the bleed-back port, and the catheter port.

The check valves reduce the need for stopcock manipulation, which in turn reduces the risk of air contamination. The bag must be tightly connected to the reservoir port of the delivery system to prevent air contamination. The bleed-back port near the catheter port allows normal saline or contrast medium injections. If CO₂ is to be injected with a guide wire in the catheter, a Y-connector (Touy-Borst) is connected to the injection port. The bag should be filled and emptied with CO₂ 3 times before the final filling to remove air from the bag.

The injection rate depends on the diameter, length, and flow of the vessels being imaged. For an abdominal aortogram or an inferior vena cavogram, 30-40 cc of CO₂ is injected. When imaging aortic branches (celiac, superior mesenteric, renal arteries) or arteries of the lower extremity, 20-30 cc is used. Because of the low viscosity of the gas, CO₂ may be injected through a 3-Fr microcatheter for selective and superselective angiography and for selective arterial embolization.

Digital subtraction angiography (DSA) should be used for CO₂ imaging. If available, a 1024 X 1024 digital subtraction angiographic system and magnification technique should be used. Stacking software for integrating a series of images has solved problems associated with the breakup of CO₂ bubbles after injection.

Respiratory motion and peristalsis become significant problems in mesenteric CO₂ angiography. Motion occurring between the time that the baseline image is made and the time that the CO₂ image is made causes marked degradation in the quality of the imaging. Additional mask images should be obtained to decrease motion artifacts by using new mask imaging subtraction. Superselective CO₂ injection into the mesenteric arterial branch with gas reflux can also improve the quality of the images. Intravenous administration of glucagon at the dose of 0.5-1 mg before CO₂ injection improves mesenteric CO₂ angiography by decreasing peristalsis.

Rapid exposures (4 to 6 frames per second) should be obtained, and superselective injection of CO₂ as close to the target vessel as possible should be performed to optimize CO₂ imaging. Elevation of target vessels 15-20° above the level of the angiographic table, as well as the intra-arterial administration of 100-150 µg of nitroglycerin, may improve filling of the peripheral arteries in the lower extremities. ^{[10, 11, 12]} Proximal arteries can be imaged by refluxing CO₂ from a peripheral injection.

CO₂ is used widely as an intravascular contrast agent for imaging both the arterial and venous circulations, particularly for patients with renal insufficiency and for patients who have a history of hypersensitivity to iodinated contrast medium. CO₂ may be used as a contrast agent for diagnostic arteriography, venography, and various vascular interventions, including renal stenting, superior mesenteric artery stenting, and endovascular aneurysm repair (EVAR). A summary of the clinical applications of CO₂ as a contrast agent for vascular diagnosis and interventions follows. ^{[13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24]}

CO₂ is frequently used as an alternative contrast agent for aortography and runoff in patients with contrast allergy and renal insufficiency (see the image below). In most patients, all outflow studies may be done with CO₂. Small amounts of iodinated contrast medium are used if needed for additional vascular information.

The technique involves the percutaneous retrograde catheterization of the femoral artery and introduction of a 4-Fr end-hole catheter, such as a shepherd hook or a Cobra-shaped catheter. An abdominal aortogram is performed with the injection of 30-40 cc of CO₂ injected at the rate of 15-20 cc per second in the anteroposterior and lateral projections. Filming is made at the rate of 4 frames per second. Then, CO₂ is injected into the distal aorta or the iliac artery to image the iliac and femoral arteries. The common and external iliac arteries can be well visualized by reflux from a common or superficial femoral artery injection. The catheter is then advanced into the contralateral superficial femoral artery for a runoff study.

If the infrapopliteal arteries are poorly visualized with a proximal injection, a 3-Fr microcatheter is advanced coaxially into the popliteal artery to image the tibial and peroneal arteries. The retrograde approach is then converted to the antegrade approach; CO₂ angiography is performed in the same fashion as on the contralateral side. For imaging of the iliac, femoral, and popliteal arteries, 20 cc of CO₂ is selectively injected.

Elevation of the legs and the intra-arterial injection of nitroglycerin (100-150 µg) allow improved visualization of the tibial and plantar branches. Because of its buoyancy and low viscosity, CO₂ may provide better filling of collateral arteries and distal branches than iodinated contrast medium provides. In 92% of cases, the vascular information provided by CO₂ angiography is adequate for a surgical or endovascular intervention.

CO₂ is most frequently used as a contrast agent for renal DSA in patients who are allergic to contrast medium or who have renal failure (see the images below). CO₂ allows visualization of the proximal renal arteries and renal artery stenoses. Because of the posterior position of the kidney relative to the aorta where CO₂ is injected, the distal renal arteries do not fill well, owing to the buoyancy of the gas.

After percutaneous femoral artery catheterization, a 4-Fr or 5-Fr catheter such as the shepherd hook catheter is advanced into the abdominal aorta; 30 to 40 cc of CO₂ is then injected into the aorta with the plastic bag delivery system in the anteroposterior projection. If filling of the renal artery is suboptimal, the patient may be rotated so as to orient the renal artery above the aorta.

Cross-table lateral imaging with the patient in the lateral decubitus position usually provides excellent filling of the renal artery. Selective renal DSA is performed with the injection of CO₂ (20 cc) into the main renal artery. For visualization of the segmental renal artery branches, a more distal injection is needed.

Following renal angioplasty and stent placement guided by CO₂, CO₂ injection distal to the stent allows visualization of the main renal artery by reflux. CO₂ angiography may allow visualization of vascular renal cell carcinoma, as well as tumor invasion of the renal vein or inferior vena cava. CO₂ may also allow visualization of the intrarenal arteriovenous fistula, stenosis, and aneurysm.

Doppler ultrasonography and magnetic resonance (MR) angiography are used as the initial diagnostic modality for the evaluation of suspected transplant renal artery stenosis. Because of the location of the renal artery anterior to the iliac artery injection site, CO₂ injection usually fills the transplant renal artery. After either ipsilateral or contralateral femoral artery catheterization, CO₂ is injected into the external iliac artery using an end-hole catheter in the anteroposterior and ipsilateral oblique projection. An injection of CO₂ into the renal artery better fills the renal artery and its branches. If a hemodynamically significant renal artery stenosis is found, balloon angioplasty and stenting can be performed using CO₂ as a contrast agent. Completion angiography is performed with the injection of CO₂ into the renal artery or into the external iliac artery.

Carbon dioxide angiography has value in selected situations requiring visceral angiography. CO₂ aortography and visceral arteriography have been found to be useful in the evaluation of the arterial anatomy, as well as in the evaluation of chronic mesenteric ischemia, aneurysms, arteriovenous fistula, and bleeding.

From the femoral artery approach, 30-40 cc of CO₂ is injected 1 to 2 cm above the celiac axis using an end-hole catheter with the plastic bag delivery system; imaging is acquired in the anteroposterior and lateral projections (see the images below). Lateral aortography is obtained during both full inspiration and expiration to evaluate median arcuate ligament compression on the celiac artery. Median arcuate ligament compression produces an extrinsic, concave impression on the cranial aspect of the celiac axis just distal to its origin at the expiratory aortogram.

Because of its low viscosity, CO₂ DSA is more sensitive than iodinated contrast medium in detecting bleeding from the GI tract, liver, and spleen. If extravasation is seen on the CO₂ aortogram, selective arteriography is performed with CO₂. Repeat arteriography is usually needed with iodinated contrast medium to provide a vascular road map before superselective catheterization of the bleeding artery for embolization. Use of CO₂ allows visualization of the visceral arterial stenoses and collaterals. CO₂ is useful in visualizing hepatocellular carcinoma and transcatheter embolization.

CO₂ angiography is useful in various oncologic interventions. The low viscosity of CO₂ allows the injection of the gas through a 3-Fr microcatheter for superselective angiography (see the images below). CO₂ may be used to assist selective embolization of renal cell carcinoma and its bone metastases and of hepatocellular carcinoma. It is also useful in placing hepatic arterial infusion catheters; for embolization of the gastroduodenal artery; for evaluation of a malfunctioning hepatic artery pump; and in hepatic arterial redistribution procedures.

Because of the low viscosity, CO₂ may be injected between the guide wire and catheter, allowing imaging before, during, and after angioplasty. CO₂ may also be injected through the sheath to guide angioplasty and stent placement. The plastic bag system provides multiple rapid injections with the guide wire in place. CO₂ has definitive advantages over iodinated contrast medium, in that its use is not associated with risks of renal toxicity or allergic reactions.

CO₂ is very useful for renal angioplasty and stent placement (see the image below). The plastic bag system allows multiple injections in various oblique projections so as to accurately position the stent. When CO₂ is injected into the renal artery, the gas always fills the renal artery with reflux of the gas into the aorta. This allows visualization of the orifice of the renal artery, which is helpful for accurately deploying the stent.

After an aortogram is obtained, the renal artery is catheterized with a 4-Fr or 5-Fr shepherd hook or a Cobra catheter, and a dual pressure recording is obtained in the renal artery distal to the stenosis and the aorta. If a significant pressure gradient is present, a 6-Fr sheath is advanced into the abdominal aorta over a 0.035-in Rosen wire. A balloon-expanding stent of appropriate diameter and length is then advanced into the renal artery stenosis. CO₂ is injected through the sheath and is imaged in multiple projections to precisely place the stent.

After stent deployment, a 4-Fr catheter (Glide Cobra catheter) is advanced into the renal artery, and the pressure gradient between the renal artery and the aorta is measured. If no significant gradient is present, CO₂ is injected through the Cobra catheter into the renal artery to visualize the stented renal artery.

EVAR is a well-accepted treatment modality for AAA. The use of CO₂ as an alternative contrast agent during EVAR may reduce the risk of renal failure. Because of its low viscosity, CO₂ may be injected through the introducer, which is preloaded with a stent graft, so as to demonstrate the renal and hypogastric artery before deployment of the stent graft. After deployment, a completion aortogram is performed with CO₂, using the Cobra catheter, to demonstrate the patency of the renal and hypogastric arteries and to identify any endoleak (see the images below).

CO₂ digital subtraction venography is safe and useful in the evaluation of the central veins of the upper extremities. Because of its low viscosity and its buoyancy, CO₂ may be injected through a 21-gauge peripheral IV access device for diagnostic central venography. The injection of CO₂ into a vein of small diameter may cause pain at the injection site. It is preferable to obtain IV access via the antecubital vein.

When 20-30 cc of CO₂ is injected into the antecubital vein, the subclavian vein becomes well filled within 5 seconds of the injection (see the image below). Occasionally, CO₂ reflux occurs into the contralateral innominate vein. CO₂ is also used for upper-extremity venography before surgical placement of an arteriovenous fistula, before transvenous pacer insertion, and before placement of a central venous catheter in selected patients. For visualization of the entire venous system of the upper extremity prior to placement of an arteriovenous fistula, an intravenous access should be made into a vein on the dorsum of the hand for CO₂ venography of the cephalic, basilic, axillary, and subclavian veins.

There are no absolute contraindications to the use of CO₂ in upper-extremity venography. Relative contraindications include severe emphysema, pulmonary hypertension, and known intracardiac septal defects or pulmonary arteriovenous malformations. Initially, small amounts of CO₂ (20 cc) should be used, so as to evaluate the effect of CO₂ on the vital signs.

The injection of CO₂ with the patient in the left lateral decubitus position facilitates the trapping of gas in the right atrium, thus preventing passage of the gas into the pulmonary arteries. Once CO₂ is injected into a vein, the gas rapidly passes through the central veins and right cardiac chambers into the pulmonary arteries. The gas trapped in the pulmonary artery is absorbed within 15 to 30 seconds in the absence of air contamination (see the image below).

The intravenous injection of CO₂ in diagnostic doses (20 to 40 cc) has no effect on vital signs. If the systolic blood pressure drops from the baseline value by 10 to 20 mm Hg, air contamination should be suspected, and the delivery system should be checked for a potential source of air contamination. CO₂ injections should be administered at intervals of 2 to 3 minutes to allow complete absorption of the gas.

CO₂ wedged hepatic venography and manometry are important in the workup of patients with cirrhosis and portal hypertension, ascites of unknown etiology, hepatic venous outflow obstruction, suspected portal vein occlusion, and TIPS; it is also important for patients who require transjugular liver biopsy (see the images below).

A 5-Fr diagnostic catheter is wedged into a peripheral hepatic vein, using either the jugular vein or femoral vein approach. An occlusion balloon catheter may also be used to occlude the hepatic vein. CO₂ is injected at a dose of 30 to 40 cc into a wedged hepatic vein to allow visualization of the intra- and extra-hepatic portal veins. In the absence of presinusoidal obstruction, the portal vein will also be visualized, regardless of the direction of the intrahepatic portal blood flow.

Wedged hepatic venography with iodinated contrast medium is used to determine the intrahepatic portal hemodynamics and to assess the morphology of the liver. The success rate of portal vein visualization with CO₂ wedged hepatic venography is approximately 90%. For a TIPS procedure, more than 1 injection may be required to fill the central portal vein before portal vein puncture.

If CO₂ wedged hepatic injections fail to show the portal vein, CO₂ is injected into the parenchyma using a 21-gauge needle. We have performed wedged hepatic venography with CO₂ and contrast medium in hundreds of patients. On several occasions, extravasation of CO₂ into the subcapsular space and peritoneal cavity has occurred. In one of these cases, transfusion was required because of bleeding. The combination of CO₂ wedged hepatic venography, hepatic manometry, and transjugular liver biopsy may provide the diagnostic information necessary for instituting appropriate therapy for patients with hepatic dysfunction.

CO₂ is a safe and effective contrast agent for inferior vena cavography in patients with contrast allergy and renal failure (see the image below). CO₂ angiography may provide accurate measurement of vena caval diameter and vascular road mapping before filter placement and vena caval interventions.

We use the plastic bag delivery system for the CO₂ injection for vena cavography. The technique used for CO₂ venography before filter placement is as follows: a 5-Fr Cobra catheter is introduced from the right femoral vein and is advanced into the contralateral iliac vein for CO₂ vena cavography to exclude the presence of a left-sided inferior vena cava. If reflux of CO₂ into the left renal vein has not occurred, the catheter is advanced into the left renal vein for a CO₂ renal venogram.

The catheter is also used to catheterize a retroaortic left renal vein. A filter is then deployed in the inferior vena cava below the lowest renal vein. If caval duplication is present, the filter is placed above the renal veins. CO₂ may demonstrate nonocclusive caval thrombus, stenosis, and occlusion. CO₂ may also be used as a contrast agent in the recanalization procedure of the occluded vena cava. Vital signs should remain stable following a bolus injection of CO₂ in amounts of 30 to 40 cc. CO₂ should be used with caution in patients with pulmonary insufficiency, pulmonary hypertension, and known intracardiac septal defects.

Splenoportography with contrast medium has been largely replaced by noninvasive imaging modalities (CTA and MRV) and arterial portography (also called indirect portography) (see the images below). Because of the low viscosity of CO₂, diagnostic quantities (15 to 30 cc of CO₂) of the gas may be injected into the splenic parenchyma, using a 22- to 25-gauge needle. Both in experimental animals and in patients, the intrasplenic injections of CO₂ cause no splenic laceration or hematoma. The splenic and portal veins are well visualized with CO₂. This technique is particularly useful in pediatric patients for whom imaging studies of portal vein patency are inconclusive; it eliminates the need for femoral artery catheterization for arterial portography.

TIPS is a well accepted means of treating patients with variceal bleeding that is unresponsive to sclerotherapy; it is also used in cases of intractable ascites and cirrhotic hydrothorax. After the right or left internal jugular vein is accessed, a 10-Fr sheath is introduced. Pressure is measured in the right atrium and the inferior vena cava. A 5-Fr Cobra catheter or a curved-tipped catheter is advanced into the right hepatic vein to measure the free hepatic vein pressure.

A CO₂ hepatic venogram is then performed with the injection of 10-15 cc of CO₂ using DSA imaging of the hepatic vein and pulmonary artery. The CO₂ trapped in the central pulmonary artery dissolves within 30 seconds after the injection. Persistence of the gas bubble over 30 seconds suggests air contamination; in such cases, the procedure should be aborted and the plastic bag system should be checked for any source of air contamination (see the image below). Vital signs should be monitored, and the blood pressure should be checked 1 minute after the initial CO₂ injection.

The catheter is then advanced until it becomes wedged. Once the catheter is wedged, the injection of 1 to 2 cc of contrast medium produces a sinusoidal blush; the wedged hepatic vein pressure is then measured. A CO₂ wedged hepatic venogram is performed with the injection of 30 to 40 cc of CO₂ and is imaged using the DSA technique.

After measuring portal vein pressure, a CO₂ splenoportogram is performed with the injection of 30 to 40 cc of CO₂. At this time, 20 cc of CO₂ or 10 cc of contrast medium is injected into the hepatic parenchymal tract and imaged with the DSA technique to rule out transgression of the hepatic artery or bile duct. CO₂ may be injected through the sheath to accurately deploy the stent from the portal vein through the parenchyma to the central hepatic vein.

If repeat pressure measurement reveals a gradient of less than 12 mm Hg between the right atrium and the portal vein, a completion digital subtraction portogram is obtained with the injection of 30 cc of CO₂.

In the CO₂ fine-needle TIPS procedure, the right or middle hepatic vein is catheterized with a 5-Fr Cobra catheter; 20 cc of CO₂ is then injected using the plastic bag system. The hepatic vein and the pulmonary artery are then imaged with DSA. The CO₂ trapped in the pulmonary artery usually dissolves within 30 seconds in the absence of air contamination.

The 21-gauge needle is then advanced from the central hepatic vein toward the portal vein, and 20 cc of CO₂ is injected through the 21-gauge needle, using the plastic bag system in the anteroposterior projection. A repeat injection is made in the left anterior oblique projection to demonstrate the position of the needle in relation to the target portal vein.

Once the 0.018-inch guidewire is advanced toward the portal vein, CO₂ is injected between the guide wire and the needle to confirm the position of the wire in the portal vein. Once the portal vein has been catheterized, the subsequent procedural steps for CO₂ administration are the same as with the large-needle TIPS procedure.

The occurrence and severity of the adverse effects of angiography may be related to the dose or to air contamination.

CO₂ aortography and celiac arteriography may cause nausea and pain lasting 2-3 minutes. No specific treatment is required. Placing the patient in a left- or right-side-up position may relieve the pain. A decrease in the doses of CO₂ usually reduces the frequency and severity of pain.

The injection of CO₂ for runoff of the lower extremities may cause pain. Decreasing the amount of CO₂ with selective injection and stacking technique helps in reducing the pain.

The injection of CO₂ into a peripheral vein for upper-extremity venography may cause pain at the injection site. The mechanism of pain is probably the explosive delivery secondary to gas compression. Purging the injection tube with 3 cc of CO₂ and administering 20-40 mg of lidocaine immediately before the injection of CO₂ for venous imaging helps in reducing the pain.

When CO₂ is trapped in an aortic aneurysm, the gas bubbles may occlude the inferior mesenteric artery, resulting in colonic ischemia.

Inadvertent injection of excessive volumes of CO₂ or air contamination may cause a vapor lock in the pulmonary artery, which results in severe hypotension. When air contamination occurs, fluoroscopy of the chest shows gas bubbles in the pulmonary artery that persists for longer than 30 seconds. If hypotension develops, the patient should be placed in the Trendelenburg and left lateral decubitus positions. If possible, air should be aspirated from the pulmonary artery using a catheter. ^{[25, 26]}

Beese RC, Bees NR, Belli AM. Renal angiography using carbon dioxide. Br J Radiol. 2000 Jan. 73(865):3-6. [Medline].

Boyd-Kranis R, Sullivan KL, Eschelman DJ, et al. Accuracy and safety of carbon dioxide inferior vena cavography. J Vasc Interv Radiol. 1999 Oct. 10(9):1183-9. [Medline].

Diaz LP, Pabon IP, Garcia JA, de la Cal Lopez MA. Assessment of CO2 arteriography in arterial occlusive disease of the lower extremities. J Vasc Interv Radiol. 2000 Feb. 11(2 Pt 1):163-9. [Medline].

Hawkins IF. Carbon dioxide digital subtraction arteriography. AJR Am J Roentgenol. 1982 Jul. 139(1):19-24. [Medline].

Sullivan KL, Bonn J, Shapiro MJ, Gardiner GA. Venography with carbon dioxide as a contrast agent. Cardiovasc Intervent Radiol. 1995 May-Jun. 18(3):141-5. [Medline].

Taylor FC, Smith DC, Watkins GE, et al. Undefined. Cardiovasc and Intervent Radiol. 1998. 22:150-151.

Kyung J. Cho, Irvin F. Hawkins. Carbon Dioxide Angiography. informa healthcare; 2007.

Caridi JG, Hawkins IF Jr, Klioze SD, Leveen RF. Carbon dioxide digital subtraction angiography: the practical approach. Tech Vasc Interv Radiol. 2001 Mar. 4(1):57-65. [Medline].

Chang TI, Chan CY, Su SK, Wang SS, Wu IH. A Novel Bubble-Mixture Method to Improve Dynamic Images in Carbon Dioxide Angiography. J Endovasc Ther. 2015 Aug. 22 (4):564-7. [Medline].

Hawkins IF, Caridi JG, Klioze SD, Mladinich CR. Modified plastic bag system with O-ring fitting connection for carbon dioxide angiography. AJR Am J Roentgenol. 2001 Jan. 176(1):229-32. [Medline].

Moresco KP, Patel NH, Namyslowski Y, et al. Carbon dioxide angiography of the transplanted kidney: technical considerations and imaging findings. AJR Am J Roentgenol. 1998 Nov. 171(5):1271-6. [Medline].

Spinosa DJ, Angle JF, Hagspiel KD, et al. Lower extremity arteriography with use of iodinated contrast material or gadodiamide to supplement CO2 angiography in patients with renal insufficiency. J Vasc Interv Radiol. 2000 Jan. 11(1):35-43. [Medline].

Eschelman DJ, Sullivan KL, Bonn J, Gardiner GA. Carbon dioxide as a contrast agent to guide vascular interventional procedures. AJR Am J Roentgenol. 1998 Nov. 171(5):1265-70. [Medline].

Hahn ST, Pfammatter T, Cho KJ. Carbon dioxide gas as a venous contrast agent to guide upper-arm insertion of central venous catheters. Cardiovasc Intervent Radiol. 1995 May-Jun. 18(3):146-9. [Medline].

Hawkins IF, Johnson AW, Caridi JG, Weingarten KE. CO2 fine-needle TIPS. J Vasc Interv Radiol. 1997 Mar-Apr. 8(2):235-9. [Medline].

Kerns SR, Hawkins IF. Carbon dioxide digital subtraction angiography: expanding applications and technical evolution. AJR Am J Roentgenol. 1995 Mar. 164(3):735-41. [Medline].

Vlachogiannakos J, Patch D, Watkinson A, et al. Carbon-dioxide portography: an expanding role?. Lancet. 2000 Mar 18. 355(9208):987-8. [Medline].

Weaver FA, Pentecost MJ, Yellin AE, et al. Clinical applications of carbon dioxide/digital subtraction arteriography. J Vasc Surg. 1991 Feb. 13(2):266-72; discussion 272-3. [Medline].

Criado E, Kabbani L, Cho K. Catheter-less angiography for endovascular aortic aneurysm repair: A new application of carbon dioxide as a contrast agent. J Vasc Surg. 2008 Jul 14. [Medline].

Mahnken AH, Bruners P, Mommertz G, Mühlenbruch G, Jacobs MJ, Günther RW, et al. Carbon dioxide contrast agent for CT arteriography: results in a porcine model. J Vasc Interv Radiol. 2008 Jul. 19(7):1055-64. [Medline].

Schatlo B, Gläsker S, Zauner A, Thompson GB, Oldfield EH, Pluta RM. Correlation of end-tidal CO2 with transcranial Doppler flow velocity is decreased during chemoregulation in delayed cerebral vasospasm after subarachnoid haemorrhage–results of a pilot study. Acta Neurochir Suppl. 2008. 104:249-50. [Medline].

Giday SA, Ko CW, Clarke JO, Shin EJ, Magno P, Jagannath SB, et al. EUS-guided portal vein carbon dioxide angiography: a pilot study in a porcine model. Gastrointest Endosc. 2007 Oct. 66(4):814-9. [Medline].

Tsukada Y, Kakuchi Y. Study on Reduction of Radiation Exposure by Using Carbon Dioxide Angiography Catheter in Vascular Access Intervention Therapy(VAIVT). Nihon Hoshasen Gijutsu Gakkai Zasshi. 2015 Sep. 71 (9):758-63. [Medline].

Higashimori A, Yokoi Y. Stent implantation for chronic total occlusion in the iliac artery using intravascular ultrasound-guided carbon dioxide angiography without iodinated contrast medium. Cardiovasc Interv Ther. 2013 Oct. 28 (4):415-8. [Medline].

Caridi JG, Hawkins IF. CO2 digital subtraction angiography: potential complications and their prevention. J Vasc Interv Radiol. 1997 May-Jun. 8(3):383-91. [Medline].

Matsuo T, Fujiwara H, Gobara H, Mimura H, Kanazawa S. Central Retinal and Posterior Ciliary Artery Occlusion After Intralesional Injection of Sclerosant to Glabellar Subcutaneous Hemangioma. Cardiovasc Intervent Radiol. 2008 Jun 20. [Medline].

Cho KJ, Hawkins IF Jr. Discontinuation of the plastic bag delivery system for carbon dioxide angiography will increase radiocontrast nephropathy and life-threatening complications. AJR Am J Roentgenol. 2011 Nov. 197(5):W940-1. [Medline].

Huang SG, Woo K, Moos JM, et al. A prospective study of carbon dioxide digital subtraction versus standard contrast arteriography in the detection of endoleaks in endovascular abdominal aortic aneurysm repairs. Ann Vasc Surg. 2013 Jan. 27(1):38-44. [Medline].

Johnston WF, Zamora AJ, Upchurch GR Jr. Transient paralysis from carbon dioxide angiography in a patient after four-vessel endovascular thoracoabdominal aortic aneurysm repair. J Vasc Surg. 2012 Dec. 56(6):1717-20. [Medline].

Koizumi J, Hashimoto T, Myojin K, et al. Carbon dioxide (CO2) vs iodinated contrast digital subtraction angiography during balloon-occluded retrograde transvenous obliteration (BRTO) using foam sclerosant for gastric varices. J Vasc Interv Radiol. 2012 Nov. 23(11):1453-1459.e1. [Medline].

Kusuyama T, Iida H, Mitsui H. Intravascular ultrasound complements the diagnostic capability of carbon dioxide digital subtraction angiography for patients with allergies to iodinated contrast medium. Catheter Cardiovasc Interv. 2012 Nov 15. 80(6):E82-6. [Medline].

Moos JM, Ham SW, Han SM, et al. Safety of carbon dioxide digital subtraction angiography. Arch Surg. 2011 Dec. 146(12):1428-32. [Medline].

Nadolski GJ, Stavropoulos SW. Contrast alternatives for iodinated contrast allergy and renal dysfunction: options and limitations. J Vasc Surg. 2013 Feb. 57(2):593-8. [Medline].

Kyung J Cho, MD, FACR, FSIR William Martel Emeritus Professor of Radiology (Interventional Radiology), Frankel Cardiovascular Center, University of Michigan Health System

Kyung J Cho, MD, FACR, FSIR is a member of the following medical societies: American College of Radiology, American Heart Association, American Medical Association, American Roentgen Ray Society, Association of University Radiologists, Radiological Society of North America

Disclosure: Nothing to disclose.

Irvin F Hawkins, Jr, MD Professor of Radiology, Professor of Surgery, University of Florida College of Medicine

Irvin F Hawkins, Jr, MD is a member of the following medical societies: Florida Medical Association, Radiological Society of North America, Society of Interventional Radiology

Disclosure: Received royalty from Angiodynamics for consulting.

Bernard D Coombs, MB, ChB, PhD Consulting Staff, Department of Specialist Rehabilitation Services, Hutt Valley District Health Board, New Zealand

Disclosure: Nothing to disclose.

Douglas M Coldwell, MD, PhD Professor of Radiology, Director, Division of Vascular and Interventional Radiology, University of Louisville School of Medicine

Douglas M Coldwell, MD, PhD is a member of the following medical societies: American Association for Cancer Research, American Heart Association, SWOG, Special Operations Medical Association, Society of Interventional Radiology, American Physical Society, American College of Radiology, American Roentgen Ray Society

Disclosure: Received consulting fee from Sirtex, Inc. for speaking and teaching; Received honoraria from DFINE, Inc. for consulting.

Eugene C Lin, MD Attending Radiologist, Teaching Coordinator for Cardiac Imaging, Radiology Residency Program, Virginia Mason Medical Center; Clinical Assistant Professor of Radiology, University of Washington School of Medicine

Eugene C Lin, MD is a member of the following medical societies: American College of Nuclear Medicine, American College of Radiology, Radiological Society of North America, Society of Nuclear Medicine and Molecular Imaging

Disclosure: Nothing to disclose.

Anthony Watkinson, MD Professor of Interventional Radiology, The Peninsula Medical School; Consultant and Senior Lecturer, Department of Radiology, The Royal Devon and Exeter Hospital, UK

Anthony Watkinson, MD is a member of the following medical societies: Radiological Society of North America, Royal College of Radiologists, Royal College of Surgeons of England

Disclosure: Nothing to disclose.

Carbon Dioxide Angiography

Research & References of Carbon Dioxide Angiography|A&C Accounting And Tax Services
Source

Share on Facebook

Tweet

Follow us